Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model - Report - MDSpire
Advertisement
Serum adropin as a potential renoprotective factor in diabetic kidney disease: evidence from a Chinese elderly cohort and an experimental mouse model
Clinical Report: Serum Adropin as a Potential Protective Agent Against DKD
Overview
This study investigates the association between serum adropin levels and diabetic kidney disease (DKD) in an elderly Chinese population, revealing that higher adropin levels correlate with a lower risk of both prevalent and incident DKD.
Background
Diabetic kidney disease (DKD) is a significant complication of diabetes mellitus, contributing to chronic kidney disease and cardiovascular issues. The increasing prevalence of DKD, especially among older adults, highlights the need for effective biomarkers.
Data Highlights
Measure
Result
Adjusted OR for prevalent DKD per 1-unit increase in adropin
0.83 (95% CI 0.71–0.96)
Adjusted HR for incident DKD per 1-unit increase in adropin
0.88 (0.85–0.91)
Median follow-up duration
6.09 years
Key Findings
Higher serum adropin levels are inversely associated with prevalent DKD.
In participants free of DKD at baseline, higher baseline adropin is linked to a lower risk of incident DKD.
RCS analyses indicate a linear cross-sectional association and a non-linear prospective association of adropin with DKD.
In a mouse model, serum adropin levels declined during DKD progression.
Adropin treatment improved renal injury indicators in the mouse model compared to untreated controls.
Clinical Implications
Further research is warranted to explore adropin's potential in DKD management.
Conclusion
The findings suggest that serum adropin is associated with both prevalent and incident DKD.
